NR Research Compound — Nicotinamide Riboside (NAD⁺ Precursor)

NR (CAS 1341-23-7, MW 255.23 Da, C₁₁H₁₄N₂O₅) is a pyridine nucleoside formed from the nicotinamide base linked to β-D-ribose via an N-glycosidic bond at the N1 position. In NAD⁺ metabolism, NR occupies a specific position in the salvage pathway: NR is phosphorylated to NMN by NRK1 (nicotinamide riboside kinase 1, cytoplasmic) and NRK2 (expressed in muscle and heart), and NMN is then adenylylated to NAD⁺ by NMNAT enzymes. NR can also enter cells via nucleoside transporters (NTs) and equilibrative nucleoside transporter 1 (ENT1/SLC29A1) without dephosphorylation — distinguishing its cellular uptake route from NMN, which requires the Slc12a8 transporter for direct entry or extracellular dephosphorylation to NR first. The two NAD⁺ precursors are thus metabolically linked but differ in uptake mechanisms, tissue distribution, and kinetic profiles in research models.

The scientific case for NR research derives from two foundational findings. First, Charles Brenner's 2004 Cell paper demonstrated that NR is an NAD⁺ precursor in Saccharomyces cerevisiae through NRK1 and that NR extends replicative lifespan in yeast in a Sir2-dependent (sirtuin-dependent) manner. Second, the NAD⁺ decline-with-aging findings (Guarente, Sinclair, de Cabo groups, 2010s–present) established that NAD⁺ levels fall progressively in multiple tissues with aging and that precursor supplementation can restore them. Key NR research milestones include: Cantó et al. (2012, Cell Metabolism) demonstrating NR supplementation increases muscle NAD⁺ and activates SIRT1/3 in rodents; Trammell et al. (2016) first human pharmacokinetics; Martens et al. (2018) showing NR raises NAD⁺ in middle-aged/older adults; and subsequent trials on muscle function, cardiovascular outcomes, and metabolic parameters. NR is the compound marketed as Niagen (ChromaDex); much of the translational research was performed in academic labs studying NAD⁺ metabolism and aging.

As a research reagent, NR is used in studies of NAD⁺ metabolism, sirtuin biology (SIRT1-7), mitochondrial function and biogenesis (PGC-1α axis), aging models, metabolic disease (NAFLD, type 2 diabetes, obesity), cardiovascular research, neurodegeneration (Alzheimer's, Parkinson's NR trial research), and NAD⁺ precursor bioavailability/pharmacokinetics. Research comparisons between NR and NMN (the two major NAD⁺ precursors) form an active area of inquiry — including tissue-specific distribution, conversion kinetics, and dose-response relationships. DMV Research supplies NR as a lyophilized compound with per-batch Certificate of Analysis confirming identity by mass spectrometry and purity ≥99% by HPLC.